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Flavonoids	   account	   for	   the	   largest	   group	   of	   secondary	  metabolites	   in	   the	   plant	   kingdom.	  
They	   comprise	   over	   5000	   ubiquitous	   compounds	   with	   a	   common	   polyphenolic	   backbone	  
(see	  Table	  1)	  and	  have	  essential	  roles	  in	  plants[1].	  	  
Among	   other	   health-­‐promoting	   properties,	   numerous	   studies	   have	   reported	   interesting	  
preclinical	  activity	   in	  cancer	  models	   for	  a	  wide	  range	  of	  cancers,	  suggesting	  their	  potential	  
use	  in	  treatment	  and	  prevention	  of	  cancer.	  This	  has	  been	  the	  basis	  for	  numerous	  studies	  and	  
trials	  in	  different	  models	  and	  types,	  including	  extensive	  research	  on	  breast	  tumours[2–4].	  
Research	  has	  reported	  the	  involvement	  of	  numerous	  mechanisms	  in	  the	  effect	  of	  flavonoids	  
against	   cancer.	   These	   are	   not	   mutually	   exclusive,	   but	   evidence	   supports	   the	   potential	   of	  
these	  compounds	  to	  target	  different	  pathways	  and	  mechanisms	  underlying	  the	  complexity	  
of	   cancer	   as	   a	   disease.	   Due	   to	   limitations	   on	   space,	   this	   review	   will	   not	   focus	   on	   the	  
numerous	  clinical	  trials	  and	  studies	  evidencing	  the	  effect	  of	  flavonoids	  on	  cancer.	  Instead,	  it	  
will	   focus	  on	   the	  most	   relevant	  of	   their	  different	  properties	  and	   summarise	   their	   complex	  
potential	  mechanism	  of	  action	  in	  breast	  cancer	  in	  particular.	  	  
Flavonoids	  as	  antioxidants	  
The	  role	  of	  flavonoids	  as	  antioxidants	  has	  been	  the	  subject	  of	  research	  for	  decades[5,6].	  The	  
numerous	   hydroxyl	   groups	   in	   the	   flavonoid	   structure,	   in	   combination	   with	   a	   highly	  
conjugated,	   π-­‐electron	   system,	   allow	   them	   to	   act	   as	   free	   radical	   scavengers	   by	   hydrogen	  
atom	   or	   electron	   donating	   activities.	   Furthermore,	   they	   can	   block	   formation	   of	   reactive	  
oxygen	   species	   (ROS),	   such	   as	   the	   hydroxyl	   radical,	   through	   chelation	   of	   redox-­‐active,	  
transition	   metal	   ions[6].	   This	   can	   have	   a	   positive	   effect	   on	   cancer	   prevention	   by	  
minimisation	  of	  phenomena	  such	  as	  oxidative	  damage	  to	  DNA.	  	  
Research	   on	   breast	   cancer	   cell	   lines	   has	   shown	   that	   polyphenols	   exert	   strong	   inhibitory	  
effects	   due	   to	   their	   antioxidant	   properties	   antagonising	   the	   oxidising	   activity	   of	   H2O2	   by	  
scavenging	   ROS,	   or	   inhibiting	   ROS	   production[7].	   Interestingly,	   there	   is	   also	   evidence	   that	  
they	   can	   act	   as	   pro-­‐oxidative	   compounds.	   For	   instance,	   myricetin	   can	   undergo	   auto-­‐
oxidation	   and	   reduce	  molecular	   oxygen	   to	   the	   superoxide	   free	   radical[8].	   This	   dual	   effect	  
suggests	  that	  a	  balance	  of	  both	  anti-­‐	  and	  pro-­‐oxidative	  properties	  might	  be	  essential	  to	  the	  
role	  of	  flavonoids	  in	  the	  prevention	  or	  treatment	  of	  disease.	  
Flavonoids	  as	  phytoestrogens	  
Some	   subtypes	   of	   flavonoids	   have	   often	   been	   referred	   to	   as	   phytoestrogens	   due	   to	   their	  
ability	   to	   mimic	   oestrogen-­‐like	   responses.	   They	   resemble	   the	   most	   important	   type	   of	  
oestrogen	   in	   humans,	   17β-­‐oestradiol	   (E2),	   due	   to	   the	   existence	   of	   hydroxyl	   groups	   and	  
phenolic	  rings	  (required	  for	  binding	  oestrogen	  receptors	  α	  and	  β	  (ERα	  and	  ERβ))[9].	  
Flavonoids	  can	  bind	  both	  isoforms	  of	  ER,	  mainly	  as	  agonists	  competing	  with	  E2[7],	   inducing	  
biological	   responses	   traditionally	   associated	  with	   the	   binding	   of	   the	   natural	   hormone	   in	   a	  
dose-­‐dependent	   manner[10,11].	   Studies	   have	   reported	   that	   some	   of	   the	   ER-­‐mediated	  
responses	   induced	   by	   flavonoids	   are	   nonetheless	   comparable,	   or	   even	   higher,	   to	   those	  
induced	  by	  physiological	  levels	  of	  E2,	  one	  reason	  why	  some	  flavonoids	  are	  still	  described	  as	  
full	  oestrogen	  agonists[12].	  	  
Unlike	   E2,	   several	   studies	   have	   reported	   a	   stronger	   affinity	   of	   flavonoids	   for	   the	   ERβ	  
isoform[13]	   and	   also	   that	   flavonoids	   binding	   ERβ	   induce	   the	   transcription	   of	   oestrogen	  
target	  genes	  to	  much	  greater	   levels	  than	  when	  binding	  ERα[14].	  Critically,	  ERβ	  is	  known	  to	  
exert	  a	  response	  opposing	  the	  proliferative	  effects	  of	  ERα	  activation[15].	  Indeed,	  interaction	  
between	  both	  types	  of	   receptors	  and	  their	  substrates	  provides	  a	  regulation	  for	   the	  overall	  
effect	   of	   oestrogens	   and	   the	   ratio	   of	   ERα/ERβ	   is	   used	   as	   a	   prognostic	   marker	   in	   breast	  
tumours[16].	   This	  means	   that	   physiological	   levels	   of	   phytoestrogens	   are	   likely	   to	   activate	  
ERβ	   but	   not	   the	   ERα-­‐mediated	   pro-­‐cancer	   signalling	   (or	   activate	   this	   to	   a	   much	   lower	  
extent),	  therefore	  facilitating	  a	  beneficial	  antiproliferative	  effect.	  
Phytoestrogens	   can	   also	   alter	   the	   level	   of	   oestrogen	   biosynthesis,	   acting	   as	   aromatase	  
inhibitors	   (AI)	   on	   cytochrome	   P450	   19	   aromatase	   (Cyp19),	   17β-­‐hydroxysteroid	  
dehydrogenases	   (HSD)	   and	  oestrone	   sulfatase	   and	   sulfotransferase[17],	   all	   involved	   in	   the	  
generation	   of	   oestradiol	   in	   breast	   tissue	   and	   associated	   with	   breast	   cancer	   when	  
overexpressed.	   Some	   flavonoids	   have	   been	   shown	   to	   induce	   a	   significant	   decrease	   in	  
circulating	   oestrogen	   concentration.	   Although	   their	   efficacy	   is	   lower	   than	   that	   of	   clinically	  
used	   steroidal	   aromatase	   inhibitors,	   they	   could	   be	   very	   beneficial	   to	   treat	   tumours	  which	  
exhibit	   a	   lack	   of	   response	   to	   common	   therapies.	   Additionally,	   flavonoids	   can	   also	   alter	  
oestrogen-­‐metabolising	   enzymes,	   thus	   reducing	   the	   production	   of	   genotoxic	   metabolites.	  
Some	   in	  vivo	   studies	  have	  been	  carried	  out	  on	  animal	  models,	  although	   the	  complexity	  of	  
these	  modulations	  needs	  to	  be	  further	  elucidated[18].	  
	  
	  




myricetin	  and	  their	  
glycosides	  
Onions,	  red	  wine,	  





Luteolin,	  apigenin	  and	  
tangeretin	  
Herbs,	  celery	  and	  




(found	  in	  diet	  mainly	  
as	  glycosides)	  





Cocoa	  or	  dark	  
chocolate,	  apples,	  
grape,	  red	  wine	  






Berries	  and	  other	  




glycitein	  and	  their	  
glycosides	  
Soy	  products	   1.2	  
Flavanonol	  
	  
Taxifolin,	  aromadedrin	   N/A	   N/A	  
Table	   1	   Flavonoids	   are	   polyphenolic	   derivates	   consisting	   of	   a	   3-­‐ring	   basic	   backbone:	   2	   fused	   ring	  
(aromatic	  A	   ring	  and	  heterocyclic	  C	   ring),	   connected	   to	  another	  aromatic	  B	   ring	   through	  a	   carbon-­‐
carbon	  bridge.	  According	  to	  changes	  in	  this	  molecular	  backbone	  and	  the	  presence	  of	  hydroxyl	  groups	  
and	  other	  moieties,	   they	   can	   then	  be	   categorised	   into	  a	   further	  7	   subclasses[1],	  most	  of	  which	  are	  
found	   in	   numerous	   dietary	   sources.	   This	   table	   includes	   examples	   compounds	   for	   each	   flavonoid	  
subclass,	  dietary	  sources	  and	  estimated	  daily	  intakes	  (E.D.I.)[19].	  Flavanonols	  have	  not	  been	  reported	  
at	  significant	  levels	  in	  dietary	  sources.	  	  
	  
Flavonoids	  as	  CYP1A1	  inhibitors/substrates	  
The	   impact	   of	   diet	   and	   environment	   in	   the	   development	   and	   progression	   of	   cancer	   is	  
partially	   due	   to	   the	   exposure	   to	   polycyclic	   aromatic	   hydrocarbons	   (PAHs)	   and	   other	  
xenobiotic	  carcinogenic	  compounds.	  PAHs	  such	  as	  benzo(α)pyrene	   (BaP),	   found	   in	   tobacco	  
smoke	   or	   charred	   foods,	   can	   give	   rise	   to	   cancer	   after	   being	   subject	   to	   oxidation	   by	  
cytochrome	  P450	  (CYP1),	  a	  family	  of	  extrahepatic	  enzymes	  with	  monooxygenase	  activity.	  	  
The	  CYP1	  family	  has	  been	  implicated	  in	  carcinogenesis	  and	  cancer	  progression	  through	  three	  
main	   mechanisms:	   firstly,	   the	   CYP1	   family	   modifies	   and	   activates	   PAHs	   and	   other	   pro-­‐
carcinogens,	   allowing	   them	   to	   bind	   DNA	   and	   give	   rise	   to	   cellular	   and	   genetic	   damage,	  
essential	   in	  the	  cancer	   initiation	  stage[20];	  secondly,	  the	  CYP1B1	  isoform	  is	   involved	   in	  the	  
modification	   of	   steroidal	   hormones	   such	   as	   oestradiol,	   contributing	   to	   the	   initiation	   of	  
mammary	   carcinogenesis[21];	   finally,	   the	   same	   isoform	   has	   also	   been	   shown	   to	   hinder	  
cancer	  treatment	  by	  inactivation	  of	  a	  range	  of	  clinically	  used	  anticancer	  drugs[22].	  
Following	   the	   role	   of	   CYP1	   in	   the	   development	   of	   cancer,	   extensive	   research	   has	   been	  
carried	  out	  to	  tackle	  its	  effects.	  Flavonoids	  such	  as	  resveratrol	  have	  been	  identified	  as	  potent	  
inhibitors	   of	   the	   induction	   of	   CYP1	   both	   ex	   vivo	   and	   in	   vivo	   by	   acting	   as	   competitive	  
antagonists	   for	   the	   aryl	   hydrocarbon	   receptor	   AhR,	   involved	   in	   the	   activation	   of	   CYP1	  
expression[23].	   This	   is	   possibly	   due	   to	   structural	   similarities	   with	   typical	   AhR	   ligands[24],	  
which	  means	  compounds	  with	  different	  structural	  features	  can	  have	  more	  potent	  inhibitory	  
effects	  in	  different	  isoforms	  of	  the	  enzyme.	  	  For	  example,	  myricetin	  and	  quercetin	  are	  potent	  
CYP1B1	  inhibitors	  but	  appeared	  to	  be	  less	  effective	  on	  the	  CYP1A1	  and	  CYP1A2	  isoforms[25].	  	  
Furthermore,	  other	  authors	  have	  reported	  the	  role	  of	  some	  flavonoids	  as	  AhR	  agonists	  and	  
CYP1	   substrates[24].	   In	   this	   case,	   the	   expression	   of	   CYP1	   isoforms	   is	   facilitated	   via	   AhR-­‐
mediated	   induction	   of	   the	   Cyp1	   gene,	   but	   structural	   similarities	   of	   flavonoids	   to	   steroid	  
hormones	  make	   flavonoids	   likely	   substrates[25],	   diminishing	   the	   harmful	   activity	   of	   CYP1	  
enzymes	  when	   they	   are	   targeted	   in	   lieu	   of	   PAHs	   and	   other	   pro-­‐carcinogens.	   Additionally,	  
enzymatic	   modification	   of	   flavonoids	   often	   gives	   rise	   to	   structures	   with	   improved	   anti-­‐
carcinogenic	  properties	  upon	  delivery	  at	  CYP1-­‐expressing	  tumour	  sites[25].	  	  
Overall,	   flavonoids	   can	   exert	   different	   effects	   on	   the	   CYP1	   family,	   acting	   either	   as	   AhR-­‐
antagonists/inhibitors,	  as	  AhR-­‐agonists/substrates	  or	  having	  a	  combined	  inhibitor/substrate	  
effect.	  The	  latter	  is	  the	  case	  with	  resveratrol,	  which	  can	  also	  be	  transformed	  into	  molecules	  
with	  improved	  anti-­‐carcinogenesis	  properties[24].	  	  
Flavonoids	  as	  ABC	  transporters	  regulators	  
The	   ABC	   (ATP-­‐binding	   cassette)	   superfamily	   is	   an	   evolutionarily-­‐conserved	   family	   of	  
transporters	   that	   comprises	   P-­‐glycoprotein	   (P-­‐gp),	   breast	   cancer	   resistance	   protein	   (BCRP,	  
also	   known	   as	   ABCG2)	   and	   multidrug	   resistance	   proteins	   1	   and	   2	   (MRP1	   and	   2).	   These	  
membrane	  proteins	  are	   involved	   in	  the	  absorption,	  disposition	  and	  secretion	  of	  xenobiotic	  
compounds.	   They	   are	   the	  main	   family	   of	   drug	   efflux	   transporters	   and	   are	   involved	   in	   the	  
disposition	  of	  clinically-­‐used	  drugs[26].	  Particularly,	  BCRP	  has	  been	  detected	  in	  a	  number	  of	  
human	   tumours,	   including	   breast	   cancer,	   and	   represents	   a	   prominent	  mechanism	   for	   the	  
development	   of	   multidrug	   resistance	   (MDR).	   Its	   overexpression	   in	   tumour	   sites	   leads	   to	  
active	  exclusion	  of	  cytotoxic	  agents,	  limiting	  their	  absorption	  and	  intracellular	  accumulation	  
and	  therefore	  hindering	  the	  effect	  of	  some	  cancer	  treatments[27].	  	  
There	  is	  accumulating	  evidence	  for	  the	  existence	  of	  flavonoid-­‐drug	  interaction	  with	  BCRP.	  In	  
the	   last	   decade	   extensive	   screenings	   have	   proved	   the	   effect	   of	   flavonoids	   as	   inhibitors	   of	  
BCRP[26,28],	  showing	  that	  their	  intake	  during	  cancer	  treatment	  can	  cause	  an	  increase	  in	  the	  
bioavailability	  and	  accumulation	  of	  antineoplastic	  agents[29],	  thus	  reversing	  MDR.	  	  
Flavonoids	  induce	  these	  effects	  by	  acting	  as	  inhibitors	  of	  the	  transporters,	  limiting	  the	  ATP-­‐
hydrolysing	  action	  that	  leads	  to	  exclusion	  of	  anticancer	  drugs	  from	  tumour	  tissues	  [30].	  This	  
probably	   takes	  place	  by	  binding	   to	  nucleotide	  binding	  domain	   (NBD),	  which	   is	   targeted	  by	  
flavonoids	   both	   in	   BCRP	   and	   P-­‐gp[31].	   Despite	   the	   positive	   alteration	   of	   drug	  
pharmacokinetics	  induced	  by	  flavonoids,	  their	  interaction	  with	  BCRP	  is	  yet	  to	  be	  completely	  
understood.	   For	   instance,	   some	   flavonoids	   can	   act	   as	   BCRP	   substrates	   (competing	   for	   the	  
transporter	   with	   other	   substrates[26]),	   whereas	   other	   compounds	   can	   even	   induce	  
expression	  of	  ABC	  transporters,	  stimulating	  BCRP-­‐mediated	  MDR[32].	  
Effect	  of	  flavonoids	  on	  apoptosis,	  cell	  cycle	  arrest	  and	  other	  signalling	  pathways	  
Numerous	   flavonoids	   have	   been	   shown	   to	   induce	   apoptosis	   in	   a	   wide	   range	   of	   cancers	  
(including	   breast[33])	   through	   both	   main	   apoptotic	   pathways:	   intrinsic,	   caspase-­‐9	   and	  
mitochondrial-­‐driven	   apoptosis;	   and	   extrinsic,	   caspase-­‐8	   and	   death	   receptor-­‐driven	  
apoptosis[34].	  	  
They	  can	  also	  modulate	  other	  important	  regulators	  of	  apoptosis,	  including	  PARP	  (poly	  ADP-­‐
ribose	   polymerase)[35],	   anti-­‐apoptotic	   protein	   families	   FLIP	   (FADD-­‐like	   inhibitory	   protein)	  
and	  Bcl-­‐2	  (B-­‐cell	  lymphoma	  2)[33,36]	  or	  regulatory	  genes	  such	  as	  p53[37].	  Flavonoids	  such	  as	  
quercetin	  can	  also	  inhibit	  proteins	  involved	  in	  the	  evasion	  of	  apoptosis,	  such	  as	  sphingosine	  
kinase[37]	  and	  protein	  kinase	  B	  (AKT)[38].	  	  
Ultimately,	   these	   discoveries	   highlight	   the	   broad	   and	   complex	   effect	   of	   flavonoids	   as	   pro-­‐
apoptotic	  drugs.	  In	  fact,	  some	  flavonoids	  have	  also	  been	  observed	  to	  play	  a	  counterintuitive	  
role	   as	   competitive	   inhibitors	   for	   some	   caspases,	   suggesting	   that	   alternative,	   non-­‐caspase	  
dependent	  apoptosis	  pathways	  may	  be	  involved	  in	  their	  actions[39].	  
Cell	   cycle	  arrest	  has	  also	  been	   identified	  as	  one	  of	   the	  main	  mechanisms	  behind	   the	  anti-­‐
tumour	  effect	  of	  flavonoids.	  Both	  naturally-­‐occurring	  and	  novel	  flavonoids	  have	  been	  shown	  
to	  arrest	  proliferation	  at	  the	  G2/M	  checkpoint	  in	  several	  different	  cancer	  types[7,37],	  mainly	  
through	  modulation	  of	  the	  expression	  level	  of	  different	  cyclins[35].	  	  
Through	  different	  mechanisms,	  linked	  to	  their	  properties	  as	  antioxidants,	  oestrogen-­‐agonists	  
or	   CYP1-­‐inhibitors,	   flavonoids	   can	   also	   modulate	   proliferation,	   invasion	   or	   inflammatory	  
signals.	   For	   instance,	   resveratrol	   inhibits	   cyclooxygenases	   1	   and	   2	   (COX1	   and	   COX2)[40],	  
involved	   in	   the	   production	   of	   prostaglandins	   that	   subsequently	   leads	   to	   cell	   proliferation,	  
angiogenesis	   and	   immunosuppression[2].	   Different	   flavonoids	   have	   also	   been	   reported	   to	  
modulate	   inflammatory	   signalling	  by	  mechanisms	   such	  as	  down-­‐regulation	  or	   inhibition	  of	  
the	  nuclear	  factor-­‐kappa	  B	  (NF-­‐κB)[41],	  therefore	  inhibiting	  proliferation	  and	  survival.	  	  
A	  recent	  meta-­‐analysis	  has	  shown	  the	  relationship	  between	  flavonoid	  consumption	  and	  the	  
reduction	  of	  chronic	  systemic	  inflammation	  mediators[42],	  while	  other	  reviews	  have	  shown	  
evidence	  supporting	  the	  ability	  of	  flavonoids	  to	  inhibit	  metastasis,	  invasion	  and	  progression	  
of	  cancer[43].	  
Promise	  of	  flavonoids	  as	  pharmacological	  agents	  against	  breast	  cancer	  
A	  major	  factor	  in	  the	  potential	  of	  flavonoids	  as	  anticancer	  agents	  lies	  in	  the	  complex	  manner	  
in	  which	  they	  exert	  different	  effects.	  Firstly,	  research	  has	  described	  the	  anti-­‐tumour	  effects	  
of	   flavonoids	   as	   being	   not	   only	   dose-­‐dependent,	   but	   also	   biphasic[36]:	   whereas	   lower	  
concentrations	  that	  could	  easily	  derive	  from	  a	  regular	  dietary	  intake	  have	  anti-­‐apoptotic	  or	  
cytoprotective	  effects,	  higher	  concentrations	  (by	  a	  factor	  of	  between	  5	  and	  10)	  can	  cause	  a	  
pro-­‐apoptotic	   response	   involving	   phenomena	   such	   as	   DNA-­‐damage[44].	   Indeed,	   low	  
concentrations	  of	  flavonoids	  such	  as	  genistein,	  resveratrol	  or	  myricetin	  may	  act	  as	  oestrogen	  
agonists	   and	   cause	   proliferation	   of	   breast	   tumour	   tissues	   in	   an	   ER-­‐dependent	   manner,	  
whereas	   higher	   concentrations	   in	   the	   micromolar	   range	   exert	   AI	   and	   cytotoxic	  
effects[10,12].	   Nevertheless,	   the	   concentrations	   required	   to	   exert	   the	   desirable	   effects	   of	  
flavonoids	   are	   still	   feasible	   from	   a	   pharmacological	   point	   of	   view,	   as	   opposed	   to	   other	  
models	  in	  which	  anti-­‐mutagens	  and	  anti-­‐carcinogens	  are	  administered	  at	  unrealistically	  high	  
doses,	  which	  would	  probably	  hinder	   the	   translation	  of	   these	   therapeutic	   strategies	   to	   the	  
clinical	   setting[45].	   Additionally,	   a	   major	   setting	   for	   the	   application	   of	   flavonoids	   is	   as	  
sensitisers	   or	   co-­‐treatments	   to	   achieve	   synergistic	   effects	   in	   combination	   with	   other	  
therapies,	  which	  means	  the	  concentrations	  required	  in	  treatment	  would	  potentially	  be	  lower	  
and	  their	  administration	  and	  delivery	  easily	  achievable.	  
Furthermore,	   the	   anti-­‐cancer	   effect	   of	   flavonoids	   has	   been	   proved	   to	   be	   broad	   (affecting	  
most	   types	   of	   cancers)	   but	   cancer-­‐specific,	   since	   normal	   cells	   remain	   unaffected	   by	  
concentrations	  that	  induce	  pro-­‐apoptotic	  effects	  on	  cancer	  cells[36].	  This	  is	  probably	  due	  to	  
the	  fact	  that	  flavonoids	  target	  pathways	  typically	  characteristic	  of	  cancer	  cells.	  For	  instance,	  
CYP1	  has	  been	  shown	  to	  be	  selectively	  expressed	  in	  tumour	  cells	  and	  pre-­‐malignant	  tissue,	  
not	   being	   significantly	   present	   in	   normal	   surrounding	   tissues[25].	   This	   shows	   a	   great	  
potential	  for	  the	  development	  of	  therapies	  targeted	  specifically	  to	  the	  abnormal	  tissue,	  and	  
this	   specificity	   could	   also	   be	   enhanced	   because	   the	   compounds	   used	   are	   often	   only	  
bioactivated	  when	  exposed	  to	  the	  effect	  of	  these	  enzymes.	  	  
Flavonoids	   also	   work	   in	   an	   additive	   manner.	   Hence,	   the	   combination	   of	   different	  
polyphenols	  administered	  concomitantly	  with	  anticancer	  treatments	  has	  been	  suggested	  as	  
one	   of	   the	   promising	   strategies	   for	   the	   application	   of	   flavonoids	   to	   cancer	   treatment[46].	  
Interestingly,	  research	  has	  also	  shown	  that	  flavonoids	  do	  not	  hinder	  other	  anticancer	  natural	  
processes	  (such	  as	  the	  effect	  of	  phase	  II	  detoxifying	  enzymes[47]).	  	  
Conclusions	  
Research	  in	  the	  last	  few	  decades	  has	  provided	  extensive	  evidence	  of	  the	  great	  versatility	  of	  
flavonoids	   and	   the	   numerous	   targets	   that	   make	   them	   a	   compound	   family	   with	   great	  
potential	  as	  anticancer	  agents.	  These	  properties	  seem	  to	  be	  largely	  linked	  to	  their	  relatively	  
simple	   structure:	   the	   presence	   of	   conjugated	   electron	   systems	   and	   aromatic	   rings	   make	  
them	  stable	  and	  reactive,	  whereas	  their	  overall	  structure	  allows	  them	  to	  act	  as	  substrates,	  
inhibitors	  or	  agonists	  for	  numerous	  enzymes	  or	  molecules	  involved	  in	  the	  development	  and	  
progression	  of	  cancer.	  	  
To	   summarise,	   the	   combination	   of	   said	   multiple	   targets	   of	   flavonoids	   and	   the	   positive	  
pharmacological	   characteristics	   of	   the	   effects	   they	   exert	   add	   up	   to	   the	   potential	   of	   these	  
compounds	  in	  cancer	  treatment.	  Such	  versatile	  biological	  activity	  implies	  a	  great	  underlying	  
complexity	   in	  the	  true	  mechanisms	  of	  action	  of	  different	  flavonoids,	  often	  dependent	  on	  a	  
fine	   balance	   between	   pro-­‐	   and	   anti-­‐oxidant	   properties	   or	   between	   other	   beneficial	   and	  
detrimental	   effects	   (see	  Figure	   1).	   	   Further	   study	   is	   needed	   for	   a	   better	   understanding	   of	  
this,	  also	  taking	  into	  consideration	  the	  consequences	  of	   long	  term	  exposure	  to	  compounds	  
as	   ubiquitous	   as	   these	   or	   the	   variable	   effects	   due	   to	   specific	   structure-­‐activity	  
relationships[29–31].	  	  
Despite	   this	   complexity,	  meta-­‐analyses	  of	   controlled	   intervention	   trials	   and	   studies	   in	   vivo	  
have	   shown	   that	   the	   application	   of	   flavonoids	   in	   the	   right	   setting	   and	   conditions	   can	  
ultimately	   lead	  to	  a	  very	  positive	  outcome:	   	  decreasing	   indicators	  of	   inflammation,	   limiting	  
proliferation,	   increasing	   latency	   and	   reducing	   both	   tumour	   size	   and	   metastasis[42].	   The	  
accumulating	  knowledge	  on	   the	  mechanism	  of	  action	  of	   flavonoids,	  as	  briefly	   summarised	  
here,	   together	   with	   information	   on	   different	   structure-­‐activity	   relationships	   has	   led	   to	  
promising	  new	   research	   rationales.	   In	   fact,	   there	   are	   several	   examples	  of	   promising	  novel	  
flavonoids	  with	   improved	  properties	   that	  are	   currently	  at	  different	   stages	  of	  development	  
towards	  their	  potential	  application	  in	  the	  treatment	  of	  ovarian	  and	  breast	  cancer[48–50].	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Figure	  1	  A	  broad	  range	  of	  beneficial	  antitumour	  properties	  have	  been	  reported	  for	  flavonoids.	  Their	  effect	  on	  oestrogen	  production	  and	  signalling	  pathways	  
has	  been	   linked	  to	   their	   role	  as	  aromatase	   inhibitors	  and	  their	   interaction	  with	  ER	  and	  oestrogen-­‐metabolising	  enzymes.	  They	  act	  as	  BCRP	   inhibitors	  and	  
interact	  with	  the	  CYP1	  both	  as	  inhibitors	  and	  substrates.	  Research	  has	  also	  shown	  their	  ability	  to	  induce	  apoptosis	  and	  cell	  cycle	  arrest	  and	  to	  alter	  numerous	  
signalling	  pathways	  involved	  in	  cancer-­‐related	  phenomena	  such	  as	  inflammation	  and	  proliferation.	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